Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3644481
Max Phase: Preclinical
Molecular Formula: C17H26N2O3
Molecular Weight: 306.41
Molecule Type: Small molecule
Associated Items:
ID: ALA3644481
Max Phase: Preclinical
Molecular Formula: C17H26N2O3
Molecular Weight: 306.41
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)(C)c1ccccc1N1CCN(C(=O)C(O)CO)CC1
Standard InChI: InChI=1S/C17H26N2O3/c1-17(2,3)13-6-4-5-7-14(13)18-8-10-19(11-9-18)16(22)15(21)12-20/h4-7,15,20-21H,8-12H2,1-3H3
Standard InChI Key: OHWQKVANIBBQSY-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 306.41 | Molecular Weight (Monoisotopic): 306.1943 | AlogP: 0.99 | #Rotatable Bonds: 3 |
Polar Surface Area: 64.01 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.40 | CX Basic pKa: 3.42 | CX LogP: 1.40 | CX LogD: 1.40 |
Aromatic Rings: 1 | Heavy Atoms: 22 | QED Weighted: 0.87 | Np Likeness Score: -0.52 |
1. (2014) Derivatives of N-acyl-N‚Ä=-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes, |
Source(1):